Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Champiat

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2019
Hyperprogression during immunotherapy: do we really want to know?S Champiat, B Besse, A Marabelle
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2024
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?I Pourmir, R Nebbache, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitorsJ-M Michot, R Pruvost, C Mateus, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2017
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapyP Pradere, J M Michot, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Novel patterns of response under immunotherapyE Borcoman, Y Kanjanapan, S Champiat, et al.
ESMO Open|September 18, 2025
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug developmentS Champiat, K Ouali, A Laparra, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 23, 2017
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatmentH Picchi, C Mateus, C Chouaid, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?J M Michot, J Lazarovici, A Tieu, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patientsM Valery, K Saleh, R Ecea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2026
Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and PitfallsO Mirallas, G Pretelli, M Balsa, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2019
Hyperprogression during immunotherapy: do we really want to know?S Champiat, B Besse, A Marabelle
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2024
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?I Pourmir, R Nebbache, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitorsJ-M Michot, R Pruvost, C Mateus, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2017
Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapyP Pradere, J M Michot, S Champiat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Novel patterns of response under immunotherapyE Borcoman, Y Kanjanapan, S Champiat, et al.
ESMO Open|September 18, 2025
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug developmentS Champiat, K Ouali, A Laparra, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 23, 2017
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatmentH Picchi, C Mateus, C Chouaid, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?J M Michot, J Lazarovici, A Tieu, et al.
Cancer Chemotherapy and Pharmacology|June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patientsM Valery, K Saleh, R Ecea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2026
Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and PitfallsO Mirallas, G Pretelli, M Balsa, et al.
Pageof 2